J. Baladi

发表

ECONOMIC ANALYSIS OF BASILIXIMAB IN RENAL TRANSPLANTATION1

H. Krueger, R. Balshaw, P. Keown, 2001 .

Economic analysis of basiliximab in renal transplantation.

H. Krueger, R. Balshaw, P. Keown, 2001, Transplantation.

The Revised Canadian Guidelines for the Economic Evaluation of Pharmaceuticals

George W. Torrance, G. Torrance, D. Menon, 1999, PharmacoEconomics.

Use of economic evaluation guidelines: 2 years' experience in Canada.

D. Menon, N. Otten, J. Baladi, 1998, Health economics.

REPORTS FROM THE CANADIAN COORDINATING OFFICE FOR HEALTH TECHNOLOGY ASSESSMENT (CCOHTA)

J. Baladi, 1999, International Journal of Technology Assessment in Health Care.

Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta-thalassemia.

H. Cario, E. Vichinsky, M. Cappellini, 2007, Clinical therapeutics.

Patient Satisfaction with Deferasirox (Exjade®, ICL670) an Oral Form of Chelation Therapy Versus Deferoxamine an Infused Chelation Therapy.

J. Ford, M. Cappellini, M. Bejaoui, 2005 .

Economic evaluation of everolimus versus sorafenib for the treatment of metastatic renal cell carcinoma after failure of first-line sunitinib.

L. Garrison, G. Di Lorenzo, Xufang Wang, 2011, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion‐dependent thalassemia: a literature review

T. Delea, T. Coates, P. Phatak, 2007, Transfusion.

Treatment Interruptions and Non-Adherence with Imatinib Mesylate and Healthcare Costs A Retrospective Analysis among Managed Care Patients with Chronic Myelogenous Leukaemia

W. Feng, H. Henk, G. Goldberg, 2007 .

Patient-reported outcomes in a phase iii study of everolimus versus placebo in patients with metastatic carcinoma of the kidney that has progressed on vascular endothelial growth factor receptor tyrosine kinase inhibitor therapy.

R. Motzer, J. Beaumont, D. Cella, 2011, The oncologist.

Progression-Free Survival: Gaining on Overall Survival as a Gold Standard and AcceleratingDrug Development

D. Lebwohl, J. Baladi, A. Kay, 2009, Cancer journal.

Association between treatment effects on disease progression (DP) endpoints and overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC).

T. Delea, A. Khuu, J. Zheng, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Disease management patterns for postmenopausal women in Europe with hormone-receptor-positive, human epidermal growth factor receptor-2 negative advanced breast cancer

P. Neven, F. André, G. Jerusalem, 2014, Current medical research and opinion.

Zoledronic acid versus pamidronate as palliative therapy in cancer patients: A Canadian time and motion analysis

K. Schulman, G. Dranitsaris, Liana DesHarnais Bruce, 2001 .

An Economic Evaluation of Finasteride for Treatment of Benign Prostatic Hyperplasia

D. Menon, N. Otten, J. Baladi, 1996, PharmacoEconomics.

Improved Treatment Satisfaction and Convenience with Deferasirox in Iron-Overloaded Patients with β-Thalassemia: Results from the ESCALATOR Trial

A. Taher, A. El‐Beshlawy, Mohsen Saleh Elalfy, 2010, Acta Haematologica.

Improved Health-Related Quality of Life in Patients with Hematological Disorders Receiving Deferasirox (Exjade®)

A. Ganser, M. Cappellini, D. Bowden, 2008 .

The impact of iron overload and its treatment on quality of life: results from a literature review

L. Abetz, D. Rofail, J. Baladi, 2006, Health and quality of life outcomes.

Patient-Reported Outcomes of Deferasirox (Exjade®, ICL670) versus Deferoxamine in Sickle Cell Disease Patients with Transfusional Hemosiderosis

P. Marks, O. Onyekwere, P. Swerdlow, 2008, Acta Haematologica.

7127 Results from additional analyses of patient reported outcomes in RECORD-1 – a randomized trial of everolimus with metastatic renal cell carcinoma patients

J. Beaumont, D. Cella, N. Hollaender, 2009 .

7131 Overall survival among metastatic renal cell carcinoma patients corrected for crossover using inverse probability of censoring weights: analyses from the everolimus phase III trial

R. Motzer, J. Zheng, J. Baladi, 2009 .

Iron chelation therapy: Clinical effectiveness, economic burden and quality of life in patients with iron overload

I. Proskorovsky, M. Viala, L. Abetz, 2008, Advances in therapy.

Clinical and economic burden of infused iron chelation therapy in the United States

J. Caro, I. Proskorovsky, K. Payne, 2007, Transfusion.

Satisfaction and adherence in patients with iron overload receiving iron chelation therapy as assessed by a newly developed patient instrument.

M. Viala, L. Abetz, K. Payne, 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Cost Effectiveness of Once-Daily Oral Chelation Therapy with Deferasirox versus Infusional Deferoxamine in Transfusion-Dependent Thalassaemia Patients

T. Delea, T. Coates, P. Phatak, 2012, PharmacoEconomics.

Research and innovation in the development of everolimus for oncology

R. Motzer, H. Lane, T. O'reilly, 2011, Expert opinion on drug discovery.

Treatment Interruptions and Non-Adherence with Imatinib and Associated Healthcare Costs

W. Feng, H. Henk, G. Goldberg, 2012, PharmacoEconomics.

Canadian Coordinating Office for Health Technology Assessment Office Canadien de Coordination de l’Évaluation des Technologies de la Santé GUIDELINES FOR ECONOMIC EVALUATION OF PHARMACEUTICALS: CANADA

Coordinator, P. Tugwell, G. Torrance, 1997 .

Cost-Effectiveness Analysis of Oral Iron Chelation Therapy with Deferasirox (Exjade®, ICL670) Versus Infusional Chelation Therapy with Deferoxamine in Patients with Transfusion-Dependent Myelodysplastic Syndrome.

T. Delea, P. Phatak, J. Baladi, 2005 .

Outcomes, utilization, and costs among thalassemia and sickle cell disease patients receiving deferoxamine therapy in the United States

T. Delea, T. Coates, P. Phatak, 2008, American journal of hematology.

Satisfaction and Adherence Significantly Improves in Patients with β-Thalassemia and Myelodysplastic Syndromes Treated with Deferasirox (Exjade®)

A. Ganser, M. Cappellini, D. Bowden, 2008 .

Satisfaction and Convenience of Chelation Therapy in Patients with Sickle Cell Disease (SCD): Comparison between Deferasirox (Exjade ® , ICL670) and Deferoxamine (DFO).

P. Marks, O. Onyekwere, P. Swerdlow, 2005 .

Compliance and persistency with imatinib.

H. Henk, G. Goldberg, J. Cortes, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

An instrument assessing satisfaction with iron chelation therapy: Psychometric testing from an open-label clinical trial

M. Cappellini, M. Viala, D. Rofail, 2010, Advances in therapy.

Total Annual Costs of Infused Iron Chelation Therapy in the United States.

I. Proskorovsky, K. Payne, M. Desrosiers, 2006 .

PHM4 COSTS AND CONSEQUENCES OF INADEQUATE COMPLIANCE WITH DEFEROXAMINE THERAPY IN PATIENTS WITH TRANSFUSION-DEPENDENT THALASSEMIA

T. Delea, T. Coates, P. Phatak, 2006 .

Costs and Consequences of Inadequate Compliance with Deferoxamine Therapy in Patients with Transfusion-Dependent Thalassemia.

T. Delea, T. Coates, P. Phatak, 2005 .

A Comparative Review of Pharmacoeconomic Guidelines

P. Jacobs, J. Baladi, J. Bachynsky, 1995, PharmacoEconomics.